Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 4 Leukemia, Myeloid, Acute 3 Colorectal Neoplasms 3 Lymphoma, Non-Hodgkin 2 Carcinoma, Basal Cell 2 Breast Diseases 2 Basal Cell Nevus Syndrome 2 Upper Tract Urothelial Carcinomas 1 Thrombocythemia, Essential 1 Solid Tumors 1 Serous Ovarian Cancer 1 Recurrence 1 Postmenopausal Women With ER+ HER2- Primary Breast Cancer 1 Polycythemia Vera 1 Ovarian Neoplasms 1 Lymphedema 1 Liver Neoplasms 1 Leukemia 1 Immunoglobulin Light-chain Amyloidosis 1 Hypogonadism 1 Glioma 1 Gastric Adenocarcinoma 1 Fatigue Syndrome, Chronic 1 Eunuchism 1 Colonic Neoplasms 1 Amyloidosis 1 Adenoma 1

Interventions

Sorafenib 68 Bevacizumab 44 Oxaliplatin 25 Doxorubicin 22 Gemcitabine 21 Fluorouracil 21 Radiosurgery 20 Nivolumab 19 durvalumab 18 Radiofrequency Ablation 18 pembrolizumab 17 lenvatinib 17 Cisplatin 17 Capecitabine 17 atezolizumab 14 Leucovorin 14 Hepatectomy 14 Radiotherapy 12 tremelimumab 10 Irinotecan 10 Drug Therapy 10 Cyclophosphamide 10 Carboplatin 10 Blood Specimen Collection 10 Ipilimumab 9 regorafenib 8 Liver Transplantation 8 Everolimus 8 Cryosurgery 8 Chemotherapy, Adjuvant 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Liver Neoplasms × Drug Evaluation × Clear all

NCT05913141 2023-06-22

PDO/PDO-TIL/PDOTS for Drug Screen

Shanghai Zhongshan Hospital

Gastrointestinal

Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡